Efficacy and Toxicity of Different Chemotherapy Protocols for Concurrent Chemoradiation in Non-Small Cell Lung Cancer-A Secondary Analysis of the PET Plan Trial
| العنوان: | Efficacy and Toxicity of Different Chemotherapy Protocols for Concurrent Chemoradiation in Non-Small Cell Lung Cancer-A Secondary Analysis of the PET Plan Trial |
|---|---|
| المؤلفون: | Thomas Hehr, Stefan Lenz, Sonja Adebahr, Hans Christian Rischke, Cornelius F. Waller, Anca-Ligia Grosu, Karin Dieckmann, Susanne Martina Eschmann, M. Tosch, Matthias Miederer, Stephanie Kremp, M. Stockinger, Eleni Gkika, Harald Binder, Andreas Küsters, Michael Mix, Tanja Schimek-Jasch, Andrea Schaefer-Schuler, Jochen Fleckenstein, Y. Bultel, Peter Hass, Jochem König, Ursula Nestle, Gabriele Holl, Alexander Thieme |
| المصدر: | Cancers Volume 12 Issue 11 Cancers, Vol 12, Iss 3359, p 3359 (2020) |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | Oncology, Cancer Research, medicine.medical_specialty, medicine.medical_treatment, NSCLC, lcsh:RC254-282, Article, chemoradiotherapy, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Internal medicine, medicine, 030212 general & internal medicine, Lung cancer, concomitant chemoradiation, non-small cell lung cancer, Cisplatin, Creatinine, Chemotherapy, business.industry, medicine.disease, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Carboplatin, Regimen, chemistry, 030220 oncology & carcinogenesis, Toxicity, business, Chemoradiotherapy, medicine.drug |
| الوصف: | (1) Background: The optimal chemotherapy (CHT) regimen for concurrent chemoradiation (cCRT) is not well defined. In this secondary analysis of the international randomized PET-Plan trial, we evaluate the efficacy of different CHT. (2) Methods: Patients with inoperable NSCLC were randomized at a 1:1 ratio regarding the target volume definition and received isotoxically dose-escalated cCRT using cisplatin 80 mg/m2 (day 1, 22) and vinorelbin 15 mg/m2 (day 1, 8, 22, 29) (P1) or cisplatin 20 mg/m2 (day 1&ndash 5, 29&ndash 33) and vinorelbin 12.5 mg/m2 (day 1, 8, 15, 29, 36, 43) (P2) or carboplatin AUC1 (day 1&ndash 33) and vinorelbin 12.5 mg/m2 (day 1, 8, 15, 29, 36, 43) (P3) or other CHT at the treating physician&rsquo s discretion. (3) Results: Between 05/2009 and 11/2016, 205 patients were randomized and 172 included in the per-protocol analysis. Patients treated in P1 or P2 had a better overall survival (OS) compared to P3 (p = 0.015, p = 0.01, respectively). Patients treated with carboplatin had a worse OS compared to cisplatin (HR 1.78, p = 0.03), but the difference did not remain significant after adjusting for age, ECOG, cardiac function creatinine and completeness of CHT. (4) Conclusions: Carboplatin doublets show no significant difference compared to cisplatin, after adjusting for possibly relevant factors, probably due to existing selection bias. |
| وصف الملف: | application/pdf |
| تدمد: | 2072-6694 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::43da6e2c05e7e8ed0ac31150e4ed3539 https://pubmed.ncbi.nlm.nih.gov/33202825 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....43da6e2c05e7e8ed0ac31150e4ed3539 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 20726694 |
|---|